Yuen Man-Fung, Fung Scott K, Tanaka Yasuhito, Kato Takanobu, Mizokami Masashi, Yuen John Chi-Hang, Wong Danny Ka-Ho, Yuan He-Jun, Sum Siu-Man, Chan Annie On-On, Wong Benjamin Chun-Yu, Lai Ching-Lung
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Rd., Hong Kong.
J Clin Microbiol. 2004 Nov;42(11):5036-40. doi: 10.1128/JCM.42.11.5036-5040.2004.
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for the probability of HBeAg seroconversion, hepatitis activity, and viral replication before and after HBeAg seroconversion and to compare the prevalence of core promoter and precore mutations. A total of 180 asymptomatic Chinese patients with CHB were monitored for a median of 53.8 months, and 38 patients with cirrhosis-related complications were studied. Hepatitis B virus (HBV) DNA levels were measured in 16 patients with HBeAg seroconversion at 3 months before, during, and 3 months after HBeAg seroconversion and in all patients at the last follow-up. Hepatitis B genotypes and core promoter and precore mutations were determined. Compared to patients with genotype C (n = 109), patients with subtype Ba (n = 69) had a higher rate of anti-HBe positivity on presentation (P = 0.05). HBeAg-positive patients with subtype Ba had a higher cumulative rate of HBeAg seroconversion than patients with genotype C (P = 0.02). However, there were no differences between the two groups with regard to the median HBV DNA levels before, during, and after HBeAg seroconversion; the probability of having persistently normal or elevated aminotransferase levels; and the median HBV DNA levels and liver biochemistry at the last follow-up. There was no difference in the prevalence of genotypes and core promoter and precore mutations between patients with and without cirrhosis-related complications. Though patients with subtype Ba had earlier HBeAg seroconversion, the liver biochemistry, HBV DNA levels in different phases of the disease, and the probability of development of cirrhosis-related complications were the same with genotypes Ba and C.
本研究旨在比较B型和C型慢性乙型肝炎(CHB)患者HBeAg血清学转换的概率、肝炎活动度以及HBeAg血清学转换前后的病毒复制情况,并比较核心启动子和前核心区突变的发生率。共对180例无症状的中国CHB患者进行了中位时间为53.8个月的监测,并对38例有肝硬化相关并发症的患者进行了研究。在16例HBeAg血清学转换患者的HBeAg血清学转换前3个月、转换期间及转换后3个月,以及所有患者的末次随访时,检测了乙肝病毒(HBV)DNA水平。确定了乙肝基因型以及核心启动子和前核心区突变情况。与C型患者(n = 109)相比,Ba亚型患者(n = 69)就诊时抗-HBe阳性率更高(P = 0.05)。Ba亚型HBeAg阳性患者的HBeAg血清学转换累积率高于C型患者(P = 0.02)。然而,两组在HBeAg血清学转换前、转换期间及转换后的HBV DNA水平中位数;转氨酶水平持续正常或升高的概率;以及末次随访时的HBV DNA水平和肝脏生化指标方面并无差异。有或无肝硬化相关并发症的患者在基因型以及核心启动子和前核心区突变发生率上没有差异。尽管Ba亚型患者HBeAg血清学转换较早,但Ba和C基因型患者在疾病不同阶段的肝脏生化指标、HBV DNA水平以及发生肝硬化相关并发症的概率是相同的。